We were long overdue for a pullback in the stock market, and we got it on Friday. The S&P 500 surged an uninterrupted 36% over the past six months to put an exclamation point on the third anniversary ...

Willingness to buy market dips is a contrarian indicator. It's a bad sign that retail investors so eagerly bought last week's stock-market dip. Last Friday, you may recall, the Dow Jones Industrial ...

A downtrend has been apparent in Cheniere Energy (LNG) lately with too much selling pressure. The stock has declined 6.1% over the past four weeks. However, given the fact that it is now in oversold ...

Zillow Group Inc. (NASDAQ: ZG) is on track for its first profitable year since 2012. The company has cited increased revenue from its mortgage business and a focus on closely managing headcount as ...

Friday’s bruising stock-market selloff unleashed a flurry of options-trading activity, as individual investors scrambled to buy the dip by scooping up bullish call options. According to data from Cboe ...

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. By Mackenzie Tatananni Follow Updated Oct 08, 2025, 11:42 am EDT / Original Oct 08, 2025, 10:12 am EDT ...

Netflix shares fell as its Q3 results fell short of analyst expectations. The biggest reason behind the miss was an expected tax charge in Brazil. However, the tax issue doesn't change the long-term ...

Mr. Market is currently offering some highly compelling bargains in the high-yield space. I share two opportunities yielding between 6-10% with strong dividend growth profiles. These opportunities ...

Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months. The shares are currently priced around $15, ...

Management has efficiently handled bringing the company back to speed, and it's now generating record demand. It's been paying down its debt at a fast clip. It's cheap today, giving the stock room to ...

Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s approaching $100 billion. This biotech has candidates in phase 2 and phase ...